Top

Published in:

Open Access 01-12-2023 | Glioblastoma | Review

Classification and function of γδT cells and its research progress in anti-glioblastoma

Authors: Yujuan Zhao, Renhong Zhu, Yashu Wang, Keqiang Wang

Published in: Discover Oncology | Issue 1/2023

Abstract

Human peripheral blood T lymphocytes are classified into alpha–beta T (αβΤ) cells and gamma–delta T (γδΤ) cells based on the difference in T cell receptors (TCRs). αβT cells are crucial for the acquired immune response, while γδΤ cells, though only a small subset, can recognize antigenic substances. These antigens do not need to be processed and presented and are not restricted by MHC. This distinguishes γδΤ cells from αβT cells and highlights their distinct role in innate immunity. Despite their small number, γδΤ cells hold significant significance in anti-tumor, anti-infection and immune regulation. Glioblastoma (GBM) represents one of the most prevalent malignant tumors within the central nervous system (CNS). Surgical resection alone proves to be an ineffective method for curing this type of cancer. Even with the combination of surgical resection, radiotherapy, and chemotherapy, the prognosis of some individuals with glioblastoma is still poor, and the recurrence rate is high. In this research, the classification, biological, and immunological functions of γδT cells and their research progress in anti-glioblastoma were reviewed.

Wang KQ, Hou YQ, Li QH, et al. Inhibitory effect of LY294002 on CD3mAb-activated T cells and Mtb-Ag-activated γδΤ cells via TCR signal transduction pathway. Int J Clin Exp Pathol. 2017;10:5538–44.

Wang KQ, Hou YQ, Gu CX, et al. Inhibitory effect of the mitogen activated protein kinase specific inhibitor PD98059 on Mtb-Ag-activated γδΤ cells. Int J Clin Exp Pathol. 2017;10:9644–8.PubMedPubMedCentral

Wang KQ, Hou YQ, Wang XH, et al. Expression kinetics of CD69 molecule by CD3+ lymphocytes and γδΤ cells under three different activating modalities. Chin J Hematol. 2014;35(8):753–4. https://doi.org/10.3760/cma.j.issn.0253-2727.2014.08.020.CrossRef

Wei L, Wang KQ, Ran ZS, Liu QH, Chen YY, Ji B, Meng L, Cao WW, An X. Auxiliary diagnostic value of γδΤ cell, IL-17, and IFN-γ levels in peripheral blood and bronchoalveolar lavage fluid for lung cancer complicated with chronic obstructive pulmonary disease. Int J Clin Exp Med. 2018;11(7):7183–91.

Chen ZW, Zhao YJ, Li XQ, Wang KQ. Study on the killing effect of γδT cells activated by Rukangyin on breast cancer MDA-MB-231 cells. Dis Mark. 2021. https://doi.org/10.1155/2021/5838582.CrossRef

Zhu RH, Yan Q, Wang YS, Wang KQ. Biological characteristics of γδT cells and application in tumor immunotherapy. Front Genet. 2023;13:1077419. https://doi.org/10.3389/fgene.2022.1077419.CrossRefPubMedPubMedCentral

Wang YS, Zhou Y, Wang KQ. γδT cells in bacterium research progress in the mechanism of disease infection. Chin J Microbiol Immunol. 2016;36(7):555–60. https://doi.org/10.3760/cma.j.issn.0254-5101,2016.07.015.CrossRef

Wang KQ, Hou YQ, Gu CX, et al. Western blotting was used to detect ZAP-70 molecule from γδΤ cells in peripheral blood. Int J Clin Exp Med. 2019;12(2):1785–90.

Wang YS, Bu WJ, Wang YR, et al. Increased values of peripheral blood γδT cells, Th17 cells, IL-17, ALT, AST, TB, and DB are closely related to the severity of chronic hepatitis B. Int J Clin Exp Med. 2019;12(6):7374–82.

10.

Wang YR, Wang YS, Wang KQ. Research progress on the mechanism of γδT cells in pathogenic microbial infection. Int J Clin Exp Med. 2019;12(8):9597–606.

11.

Zhao NG, Zhang JP, Zhang TT, et al. Expression of γδT and CD4+ CD25+ T cells in peripheral blood of HIV-infected patients/AIDS patients and their correlation. Chin J Microbiol Immunol. 2021;41(7):524–30. https://doi.org/10.3760/cma.j.cn112309-20200618-00322.CrossRef

12.

Zhao NG, Zhang TT, Zhao YJ, Zhang JP, Wang KQ. CD3+T, CD4+T, CD8+T, and CD4+T/CD8+T ratio and quantity of γδT cells in peripheral blood of HIV-infected/AIDS patients and its clinical significance. Comput Math Methods Med. 2021;2021: 8746264. https://doi.org/10.1155/2021/8746264.CrossRefPubMedPubMedCentral

13.

Faustino AC, Viani GA, Hamamura AC. Patterns of recurrence and outcomes of glioblastoma multiforme treated with chemoradiation and adjuvant temozolomide. Clinics. 2020;75: e1553. https://doi.org/10.6061/clinics/2020/e1553.CrossRefPubMedPubMedCentral

14.

Śledzińska P, Bebyn MG, Furtak J, et al. Prognostic and predictive biomarkers in gliomas. Int J Mol Sci. 2021;22(19):10373. https://doi.org/10.3390/ijms221910373.CrossRefPubMedPubMedCentral

15.

Zhang M, Lu XL, Wei CR, et al. Association between αβ and γδT-cell subsets and clinicopathological characteristics in patients with breast cancer. Oncol Lett. 2020;20:3251–8. https://doi.org/10.3892/ol.2020.12188.CrossRef

16.

Bonneville M, O’Brien RL, Born WK. Gammadelta T cell effector functions: a blend of innate programming and acquired plasticity. Nat Rev Immunol. 2010;10(7):467–78. https://doi.org/10.1038/nri2781.CrossRefPubMed

17.

Chen ZW, Zhao YJ, Wang KQ. γδT cells: in-vitro expansion and its use in tumor therapy. Chin J Biomed Eng. 2022;28(1):98–104. https://doi.org/10.3760/cma.j.cn115668-20200616-00154.CrossRef

18.

Caccamo N, La Mendola C, Orlando V, Meraviglia S, Todaro M, Stassi G, et al. Differentiation, phenotype, and function of interleukin-17-producing human Vgamma9Vdelta2 T cells. Blood. 2011;118(1):129–38. https://doi.org/10.1182/blood-2011-01-331298.CrossRefPubMed

19.

Caccamo N, Meraviglia S, Ferlazzo V, et al. Differential requirements for antigen or homeostatic cytokines for proliferation and differentiation of human Vgamma9Vdelta2 naive, memory and effector T cell subsets. Eur J Immunol. 2005;35(6):1764–72. https://doi.org/10.1002/eji.200525983.CrossRefPubMed

20.

Mangan BA, Dunne MR, O’Reilly VP, et al. Cutting edge: CD1d restriction and Th1/Th2/Th17 cytokine secretion by human Vδ3 T cells. J Immunol. 2013;191(1):30–4. https://doi.org/10.4049/jimmunol.1300121.CrossRefPubMed

21.

Harly C, Peyrat MA, Netzer S, Déchanet-Merville J, Bonneville M, Scotet E. Up-regulation of cytolytic functions of human Vδ2-γ T lymphocytes through engagement of ILT2 expressed by tumor target cells. Blood. 2011;117(10):2864–73. https://doi.org/10.1182/blood-2010-09-309781.CrossRefPubMed

22.

Pang DJ, Neves JF, Sumaria N, Pennington DJ. Understanding the complexity of gammadelta T-cell subsets in mouse and human. Immunology. 2012;136(3):283–90. https://doi.org/10.1111/j.1365-2567.2012.03582.x.CrossRefPubMedPubMedCentral

23.

Jensen KD, Su X, Shin S, et al. Thymic selection determines gammadelta T cell effector fate: antigen-native cells make interleukin-17 and antigen-experienced cells make interferon gamma. Immunity. 2008;29(1):90–100. https://doi.org/10.1016/j.immuni.2008.04.022.CrossRefPubMedPubMedCentral

24.

Conroy MJ, Mac Nicholas R, Taylor M, O’Dea S, Mulcahy F, Norris S, Doherty DG. Increased frequencies of circulating IFN-γ-producing Vδ1+ and Vδ2+γδT cells in patients with asymptomatic persistent hepatitis B virus infection. Viral Immunol. 2015;28(4):201–8. https://doi.org/10.1089/vim.2014.0133.CrossRefPubMed

25.

Umemura M, Yahagi A, Hamada S, et al. IL-17-mediated regulation of innate and acquired immune response against pulmonary mycobacterium bovisbacille Calmette-Guerin infection. J Immunol. 2007;178(6):3786–96. https://doi.org/10.4049/jimmunol.178.6.3786.CrossRefPubMed

26.

Okamoto Yoshida Y, Umemura M, Yahagi A, et al. Essential role of IL-17A in the formation of a mycobacterial infection-induced granuloma in the lung. J Immunol. 2010;184(8):4414–22.CrossRefPubMed

27.

SilVa-Santos B. Promoting angiogenesis within the tumor microenvironment: the secret life of murine lymphoid IL-17-producing gammadelta T cells. Eur J Immunol. 2010;40(7):1873–6.CrossRefPubMed

28.

Wu P, Wu D, Ni C, et al. γδT17 cells promote the accumulation and expansion of myeloid-derived suppressor cells in human colorectal cancer. Immunity. 2014;40(5):785–800.CrossRefPubMedPubMedCentral

29.

Agerholm R, Bekiaris V. Evolved to protect, designed to destroy: IL-17-producing γδ T cells in infection, inflammation, and cancer. Eur J Immunol. 2021;51:2164–77. https://doi.org/10.1002/eji.202049119.CrossRefPubMed

30.

Li X, Kang N, Zhang X, Dong X, Wei W, Cui L, Ba D, He W. Generation of human regulatory gammadelta T cells by TCR gammadelta stimulation in the presence ofTGF-beta and their involvement in the pathogenesis of systemiclupus erythematosus. J Immunol. 2011;186(12):6693–700. https://doi.org/10.4049/jimmunol.1002776.CrossRefPubMed

31.

Ye J, Ma C, Hsueh EC, et al. Tumor-derivedγδregulatory T cells suppress innate and adaptive immunity through the induction ofimmunosenescence. J Immunol. 2013;190(5):2403–14. https://doi.org/10.4049/jimmunol.1202369.CrossRefPubMed

32.

Hu Y, Cui Q, Gu Y, et al. Decitabine facilitates the generation and immunosuppressive function of regulatory γδT cells derived fromhuman peripheral blood mononuclear cells. Leukemia. 2013;27(7):1580–5. https://doi.org/10.1038/leu.2012.345.CrossRefPubMed

33.

Gong GG, Shao LY, Wang YQ, Chen CY, Huang D, Yao SY, Zhan XM, Sicard H, Wang R, Chen ZW. Phosphoantigen-activated V gamma 2V delta 2 T cells antagonize IL-2-induced CD4+CD25+Foxp3+T regulatory cells in mycobacterial infection. Blood. 2009;113:837–45. https://doi.org/10.1182/blood-2008-06-162792. (Epub 2008 Nov 3).CrossRefPubMedPubMedCentral

34.

Kühl AA, Pawlowski NN, Grollich K, et al. Human peripheral γδT cells possess regulatory potential. Immunology. 2009;128:580–8. https://doi.org/10.1111/j.1365-2567.2009.03162.CrossRefPubMedPubMedCentral

35.

Poonia B, Pauza CD. Gamma delta T cells from HIV+ donors can be expanded in vitro by zoledronate/interleukin-2 to become cytotoxic effectors for antibody-dependent cellular cytotoxicity. Cytotherapy. 2012;14(2):173–81. https://doi.org/10.3109/14653249.2011.623693.CrossRefPubMed

36.

Khatri M, Dwivedi V, Krakowka S, et al. Swine influenza H1N1 virus induces acute inflammatory immune responses in pig lungs: a potential animal model for human H1N1 influenza virus. J Virol. 2010;84(21):11210–8. https://doi.org/10.1128/JVI.01211-10.CrossRefPubMedPubMedCentral

37.

Wen MJ, Liu M, Zhang XL, Cao B. Distribution of γδT17/Th17/Tc17 cells in lung of H1N1 infected mice and their relationship with immunologic injury of lung. Chin J Immunol. 2017;33(6):563–8. https://doi.org/10.3969/j.issn.1000-484X.2017.04.018.CrossRef

38.

Sánchez Martínez D, Tirado N, Mensurado S, Martínez-Moreno A, Romecín P, Gutiérrez Agüera F, et al. Generation and proof- of- concept for allogeneic CD123 CAR-delta one T (DOT) cells in acute myeloid leukemia. J Immunother Cancer. 2022;10(9): e005400. https://doi.org/10.1136/jitc-2022-005400.CrossRefPubMedPubMedCentral

39.

Ang WX, Ng YY, Xiao L, Chen C, Li Z, Chi Z, et al. Electroporation of NKG2D RNA CAR improves Vgamma9Vdelta2 T cell responses against human solid tumor xenografts. Mol Ther Oncolytics. 2020;17:421–30. https://doi.org/10.1016/j.omto.2020.04.013.CrossRefPubMedPubMedCentral

40.

Rozenbaum M, Meir A, Aharony Y, Itzhaki O, Schachter J, Bank I, et al. Gamma–delta CAR-T-cells show CAR-directed and independent activity against leukemia. Front Immunol. 2020;11:1347. https://doi.org/10.3389/fimmu.2020.01347.CrossRefPubMedPubMedCentral

41.

Makkouk A, Yang XC, Barca T, Lucas A, Turkoz M, Wong JTS, et al. Off-the-shelf Vdelta1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma. J Immunother Cancer. 2021;9(12): e003441. https://doi.org/10.1136/jitc-2021-003441.CrossRefPubMedPubMedCentral

42.

Nakajima J, Murakawa T, Fukami T, et al. A phase I study of adoptive immunotherapy for recurrent non-small-cell lung cancer patients with autologous γδT cells. Eur J Cardio Thorac Surg. 2010;37(5):92–103. https://doi.org/10.1016/j.ejcts.2009.11.051.CrossRef

43.

Beck BH, Kim HG, Kim H, et al. Adoptively transferred ex vivo expanded γδT cells mediate in vivo antitumor activity in preclinical mouse models of breast cancer. Breast Cancer Res Treat. 2010;122(1):135–44. https://doi.org/10.1007/s10549-009-0527-6.CrossRefPubMed

44.

Wen K, Bui T, Li G, et al. Characterization of immune modulating functions of γδT cell subsets in a gnotobiotic pig model of human rotavirus infection. Comp Immunol Microbiol Infect Dis. 2012;35(4):289–301. https://doi.org/10.1016/j.cimid.2012.01.010.CrossRefPubMedPubMedCentral

45.

Nedellec S, Sabourin C, Bonneville M, Scotet E. NKG2D costimulates human Vγ9Vδ2 T cell antitumor cytotoxicity through protein kinase C theta-dependent modulation of early TCR-induced calcium and transduction signals. J Immunol. 2010;185(1):55–63. https://doi.org/10.4049/jimmunol.1000373.CrossRefPubMed

46.

Li Z. Potential of human γδT cells for immunotherapy of osteosarcoma. Mol Biol Rep. 2013;1:132–40.

47.

Hanagiri T, Shigematsu Y, Kuroda K, et al. Antitumor activity of human γδT cells transducted with CD 8 and with T-cell receptors of tumor-specific cytotoxic T lymphocytes. Cancer Sci. 2012;103(8):232–9. https://doi.org/10.1111/j.1349-7006.2012.02337.x.CrossRef

48.

Cobbs CS, Soroceanu L, Denham S, et al. Human cytomegalovirus induces cellular tyrosine kinase signaling and promotes glioma cell invasiveness. J Neurooncol. 2007;85(3):271–80. https://doi.org/10.1007/s11060-007-9423-2.CrossRefPubMed

49.

Marlin R, Pappalardo A, Kaminski H, et al. Sensing of cell stress by human gammadelta TCR-dependent recognition of annexin A2. Proc Natl Acad Sci USA. 2017;114(12):3163–8. https://doi.org/10.1073/pnas.1621052114.CrossRefPubMedPubMedCentral

50.

Day BW, Stringer BW, Boyd AW. Eph receptors as therapeutic targets in glioblastoma. Br J Cancer. 2014;111(7):1255–61. https://doi.org/10.1038/bjc.2014.73.CrossRefPubMedPubMedCentral

51.

Jarry U, Chauvin C, Joalland N, et al. Stereotaxic administrations of allogeneic human Vgamma9Vdelta2 T cells efficiently control the development of human glioblastoma brain tumors. Onco Targets Ther. 2016;5(6): e1168554. https://doi.org/10.1080/2162402X.2016.1168554.CrossRef

52.

Chitadze G, Kabelitz D. Immune surveillance in glioblastoma: role of the NKG2D system and novel cell- based therapeutic approaches. Scand J Immunol. 2022;96: e13201. https://doi.org/10.1111/sji.13201.CrossRefPubMed

53.

Qin G, Mao H, Zheng J, et al. Phosphoantigen-expanded human γδT cells display potent cytotoxicity against monocyte-derived macrophages infected with human and avian influenza viruses. J Infect Dis. 2009;200:858–65. https://doi.org/10.1086/605413.CrossRefPubMed

54.

Kubota K. Innate IFN-γ production by subsets of natural killer cells, natural killer T cells and γδT cells in response to dying bacterial-infected macrophages. Scand J Immunol. 2010;71:199–209. https://doi.org/10.1111/j.1365-3083.2009.02366.x.CrossRefPubMed

55.

Wu Y, Wu W, Wong WM, Ward E, Thrasher AJ, Goldblatt D, Osman M, Digard P, Canaday DH, Gustafsson K. Human γδT cells: a lymphoid lineage cell capable of professional phagocytosis. J Immunol. 2009;183(9):5622–9. https://doi.org/10.4049/jimmunol.0901772.CrossRefPubMed

56.

Puttur FK, Fernandez MA, White R, Roediger B, Cunningham AL, Weninger W, Jones CA. Herpes simplex virus infects skin γδT cells before Langerhans cells and impedes migration of infected Langerhans cells by inducing apoptosis and blocking E-cadherin downregulation. J Immunol. 2010;185(1):477–87. https://doi.org/10.4049/jimmunol.0904106.CrossRefPubMed

57.

Chodaczek G, Papanna V, Zal MA, Zal T. Erratum: Body-barrier surveillance by epidermal γδTCRs. Nat Immunol. 2012;13(3):272–82. https://doi.org/10.1038/ni.2240.CrossRefPubMedPubMedCentral

58.

Belghali MY, El Moumou L, Hazime R, Brahimi M, El Marrakchi M, Belaid HA, et al. Phenotypic characterization of human peripheral γδT-cell subsets in glioblastoma. Microbiol Immunol. 2022;66(10):465–76. https://doi.org/10.1111/1348-0421.13016.CrossRefPubMed

59.

Yue CB, Yang K, Wang QD, Hu FX, Zhao SM, Liu SQ. γδT cells in peripheral blood of glioma patients. Med Sci Monit. 2018;24:1784–92. https://doi.org/10.12659/MSM.905932.CrossRefPubMedPubMedCentral

60.

Bryant NL, Suarez-Cuervo C, Gillespie GY, Markert JM, Nabors LB, Meleth S, Lopez RD, Lamb LS. Characterization and immunotherapeutic potential of γδT-cells in patients with glioblastoma. Neuro Oncol. 2009;11(4):357–67. https://doi.org/10.1215/15228517-2008-111.CrossRefPubMedPubMedCentral

61.

Lee M, Park C, Woo J, Kim J, Kho I, Nam D-H, Park W-Y, Kim Y-S, Kong D-S, Lee HW, Kim TJ. Preferential infiltration of unique Vγ9Jγ2-Vδ2 T cells into glioblastoma multiforme. Front Immunol. 2019;10:555. https://doi.org/10.3389/fimmu.2019.00555.CrossRefPubMedPubMedCentral

62.

Dunne MR, Mangan BA, Madrigal-Estebas L, Doherty DG. Preferential Th1 cytokine profile of phosphoantigen-stimulated human Vgamma9Vdelta2 T cells. Mediators Inflamm. 2010;2010: 704941. https://doi.org/10.1155/2010/704941.CrossRefPubMed

63.

Caccamo N, Todaro M, Sireci G, Meraviglia S, Stassi G, Dieli F. Mechanisms underlying lineage commitment and plasticity of human gammadelta T cells. Cell Mol Immunol. 2013;10(1):30–4. https://doi.org/10.1038/cmi.2012.42.CrossRefPubMed

64.

Casetti R, Agrati C, Wallace M, Sacchi A, Martini F, Martino A, et al. Cutting edge: TGF-beta1 and IL-15 induce FOXP3+ gammadelta regulatory T cells in the presence of antigen stimulation. J Immunol. 2009;183:3574–7. https://doi.org/10.4049/jimmunol.0901334.CrossRefPubMed

65.

Nakazawa T, Nakamura M, Park YS, Motoyama Y, Hironaka Y, Nishimura F, et al. Cytotoxic human peripheral blood-derived γδT cells kill glioblastoma cell lines: implications for cell-based immunotherapy for patients with glioblastoma. J Neurooncol. 2014;116:31–9. https://doi.org/10.1007/s11060-013-1258-4.CrossRefPubMed

66.

Bryant NL, Gillespie GY, Lopez RD, Markert JM, Cloud GA, Langford CP, et al. Preclinical evaluation of ex vivo expanded/activated γδT cells for immunotherapy of glioblastoma multiforme. J Neurooncol. 2011;101:179–88. https://doi.org/10.1007/s11060-010-0245-2.CrossRefPubMed

67.

Bryant NA, Rash AS, Woodward AL, Medcalf E, Helwegen M, Wohlfender F, et al. Isolation and characterisation of equine influenza viruses (H3N8) from Europe and North America from 2008 to 2009. Vet Microbiol. 2011;147(1–2):19–27. https://doi.org/10.1016/j.vetmic.2010.05.040.CrossRefPubMed

68.

Cherry ABC, Gherardin NA, Sikder HI. Intracellular radar: understanding γδT cell immune surveillance and implications for clinical strategies in oncology. Front Oncol. 2022;12:1011081. https://doi.org/10.3389/fonc.2022.1011081.CrossRefPubMedPubMedCentral

69.

Poggi A, Carosio R, Fenoglio D, Brenci S, Murdaca G, Setti M, et al. Migration of V delta 1 and V delta 2 T cells in response to CXCR3 and CXCR4 ligands in healthy donors and HIV-1-infected patients: competition by HIV-1 Tat. Blood. 2004;103:2205–13. https://doi.org/10.1182/blood-2003-08-2928.CrossRefPubMed

70.

Correia DV, Lopes A, Silva-Santos B. Tumor cell recognition by gammadelta T lymphocytes: T-cell receptor vs. NK-cell receptors. Oncoimmunology. 2013;2(1): e22892. https://doi.org/10.4161/onci.22892.CrossRefPubMedPubMedCentral

71.

Kong Y, Cao W, Xi X, Ma C, Cui L, He W. The NKG2D ligand ULBP4 binds to TCRgamma9/delta2 and induces cytotoxicity to tumor cells through both TCR gammadelta and NKG2D. Blood. 2009;114:310–7. https://doi.org/10.1182/blood-2008-12-196287.CrossRefPubMed

72.

Dai Y, Chen H, Mo C, Cui L, He W. Ectopically expressed human tumor biomarker MutS homologue 2 is a novel endogenous ligand that is recognized by human gammadelta T cells to induce innate anti-tumor/virus immunity. J Biol Chem. 2012;287(20):16812–9. https://doi.org/10.1074/jbc.M111.327650.CrossRefPubMedPubMedCentral

73.

Vantourout P, Mookerjee-Basu J, Rolland C, Pont F, Martin H, Davrinche C, et al. Specific requirements for Vgamma9Vdelta2 T cell stimulation by a natural adenylated phosphoantigen. J Immunol. 2009;183(6):3848–57. https://doi.org/10.4049/jimmunol.0901085.CrossRefPubMed

74.

Cimini E, Piacentini P, Sacchi A, Gioia C, Leone S, Lauro GM, et al. Zoledronic acid enhances Vδ2T-lymphocyte antitumor response to human glioma cell lines. Int J Immunopathol Pharmacol. 2011;24(1):139–48. https://doi.org/10.1177/039463201102400116.CrossRefPubMed

75.

Nakazawa T, Nakamura M, Matsuda R, Nishimura F, Park YS, Motoyama Y, et al. Antitumor effects of minodronate, a third-generation nitrogen-containing bisphosphonate, in synergy with gammadelta T cells in human glioblastoma in vitro and in vivo. J Neurooncol. 2016;129:231–41. https://doi.org/10.1007/s11060-016-2186-x.CrossRefPubMed

76.

Lamb LS. γδT cells as immune effectors against high-grade gliomas. Immunol Res. 2009;45:85–95. https://doi.org/10.1007/s12026-009-8114-9.CrossRefPubMed

77.

Gober HJ, Kistowska M, Angman L, Jenö P, Mori L, De Libero G. Human T cell receptor γδ cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med. 2003;197(2):163–8. https://doi.org/10.1084/jem.20021500.CrossRefPubMedPubMedCentral

78.

Oizel K, Chauvin C, Oliver L, Gratas C, Geraldo F, Jarry U, et al. Efficient mitochondrial glutamine targeting prevails over glioblastoma metabolic plasticity. Clin Cancer Res. 2017;23(20):6292–304. https://doi.org/10.1158/1078-0432.CCR-16-3102.CrossRefPubMed

79.

Joalland N, Chauvin C, Oliver L, Vallette FM, Pecqueur C, Jarry U, Scotet E. IL-21 increases the reactivity of allogeneic human Vγ9Vδ2 T cells against primary glioblastoma tumors. J Immunother. 2018;41(5):224–31. https://doi.org/10.1097/CJI.0000000000000225.CrossRefPubMed

80.

Chitadze G, Lettau M, Luecke S, Wang T, Janssen O, Fürst D, et al. NKG2D- and T-cell receptor-dependent lysis of malignant glioma cell lines by human γδT cells: modulation by temozolomide and A disintegrin and metalloproteases 10 and 17 inhibitors. OncoImmunology. 2015;5(4): e1093276. https://doi.org/10.1080/2162402X.2015.1093276.CrossRefPubMedPubMedCentral

81.

Flüh C, Chitadze G, Adamski V, Hattermann K, Synowitz M, Kabelitz D, et al. NKG2D ligands in glioma stem-like cells: expression in situ and in vitro. Histochem Cell Biol. 2018;149:219–33.CrossRefPubMed

82.

Lamb LS Jr, Bowersock J, Dasgupta A, Gillespie GY, Su Y, Johnson A, Spencer HT. Engineered drug resistant gammadelta T cells kill glioblastoma cell lines during a chemotherapy challenge: a strategy for combining chemo- and immunotherapy. PLoS ONE. 2013;8(1): e51805. https://doi.org/10.1371/journal.pone.0051805.CrossRefPubMedPubMedCentral

83.

Lamb LS, Pereboeva L, Youngblood S, Gillespie GY, Nabors LB, Markert JM, et al. A combined treatment regimen of MGMT-modified γδT cells and temozolomide chemotherapy is effective against primary high grade gliomas. Sci Rep. 2021;11(1):21133. https://doi.org/10.1038/s41598-021-00536-8.CrossRefPubMedPubMedCentral

84.

Chauvin C, Joalland N, Perroteau J, Jarry U, Lafrance L, Willem C, et al. NKG2D controls natural reactivity of Vgamma9Vdelta2 T lymphocytes against mesenchymal glioblastoma cells. Clin Cancer Res. 2019;25:7218–28. https://doi.org/10.1158/1078-0432.CCR-19-0375.CrossRefPubMed

Title: Classification and function of γδT cells and its research progress in anti-glioblastoma
Authors: Yujuan Zhao
Renhong Zhu
Yashu Wang
Keqiang Wang
Publication date: 01-12-2023
Publisher: Springer US
Keywords: Glioblastoma
Glioblastoma
Glioblastoma
Published in: Discover Oncology / Issue 1/2023
Print ISSN: 1868-8497
Electronic ISSN: 2730-6011
DOI: https://doi.org/10.1007/s12672-023-00770-8

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2023

ZDHHC9: a promising therapeutic target for triple-negative breast cancer through immune modulation and immune checkpoint blockade resistance

BLCA prognostic model creation and validation based on immune gene-metabolic gene combination

Machine learning-based predictive model for the differential diagnosis of ≤ 5 cm gastric stromal tumor and gastric schwannoma based on CT images

Correction: MUC13 promotes the development of esophageal cancer by upregulating the expression of o-glycan process-related molecules

Advances of exosomal miRNAs in the diagnosis and treatment of ovarian cancer

Rapid identification of endometrial hyperplasia and endometrial endometrioid cancer in young women

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials